Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Orthofix Medical is a global medical device company specializing in musculoskeletal healing products across spine fixation, bone growth stimulation, and orthopedic solutions. The company operates through two primary segments: Global Spine (spinal implants, biologics) and Global Orthopedics (bone growth stimulators, sports medicine), serving hospitals, ambulatory surgery centers, and physicians primarily in the US and international markets. Currently undergoing operational restructuring with negative operating margins despite strong gross margins, indicating pricing power but operational inefficiency.
Orthofix generates revenue through direct sales forces and distributor networks selling premium-priced orthopedic devices to hospitals and surgical centers. The 68.3% gross margin reflects strong pricing power from proprietary technologies (bone growth stimulation, biologics) and regulatory barriers to entry (510(k) clearances, PMA approvals). Revenue model combines one-time capital equipment sales with higher-margin recurring consumables. Competitive advantages include established surgeon relationships, clinical evidence supporting product efficacy, and comprehensive product portfolios that create switching costs. However, negative 10.6% operating margin indicates excessive SG&A spending relative to revenue scale, likely from maintaining direct sales infrastructure and ongoing R&D investments.
Spine implant procedure volumes in the US, driven by elective surgery trends and hospital capacity utilization
New product launches and FDA clearances, particularly in biologics and minimally invasive spine technologies
Operating margin improvement trajectory and path to profitability, given current negative margins
International revenue growth, particularly in Europe and emerging markets where penetration remains lower
Competitive share gains or losses in bone growth stimulation market against Zimmer Biomet and Stryker
Medicare reimbursement rate pressure for spine procedures and bone growth stimulation devices, with CMS increasingly scrutinizing medical necessity and cost-effectiveness
Shift toward outpatient and ambulatory surgery centers reducing average selling prices and changing distribution economics
Technological disruption from robotics-assisted surgery platforms (Globus Medical, Medtronic) requiring significant R&D investment to remain competitive
Regulatory pathway complexity and lengthening FDA approval timelines for novel biologics and combination products
Intense competition from larger, better-capitalized competitors (Medtronic, Stryker, Zimmer Biomet, Johnson & Johnson) with broader product portfolios and stronger surgeon relationships
Consolidation among orthopedic device manufacturers creating scale disadvantages in R&D spending and commercial reach
Hospital group purchasing organization (GPO) contracts favoring larger suppliers with comprehensive portfolios, limiting market access
Generic competition in mature product categories like traditional bone growth stimulators as patents expire
Negative free cash flow of -$0.0B (approximately -1.7% FCF yield) creates cash burn concern if operational improvements don't materialize
Continued operating losses strain liquidity despite adequate current ratio, potentially requiring capital raises or debt refinancing
Working capital management critical given negative cash generation; inventory obsolescence risk in medical devices with evolving technology
moderate - Elective orthopedic and spine procedures exhibit cyclical sensitivity as patients defer non-urgent surgeries during economic uncertainty or when employment-based insurance coverage weakens. However, trauma-related procedures and medically necessary spine surgeries provide revenue stability. Hospital capital equipment budgets tighten during recessions, impacting device sales. The 7.1% revenue growth suggests resilience but not immunity to macro conditions. Commercial insurance mix (higher reimbursement) versus Medicare/Medicaid affects profitability.
Rising interest rates have modest negative impact through two channels: (1) hospital capital budgets contract as financing costs increase, potentially delaying equipment purchases, and (2) higher discount rates compress valuation multiples for unprofitable growth companies. With 0.46x debt/equity ratio, direct financing cost impact is manageable. However, the company's negative earnings make it more sensitive to risk-free rate changes affecting growth stock valuations. Customer financing programs for capital equipment could see reduced demand in higher rate environments.
Minimal direct credit exposure. Revenue is primarily from hospitals and surgery centers with stable payment histories, though reimbursement pressure from government and commercial payers affects end-market demand. Working capital appears healthy with 2.47x current ratio. Primary credit concern is the company's own access to capital markets if operational losses persist, though current balance sheet appears adequate for near-term needs.
value - The 0.7x price/sales ratio and 1.2x price/book suggest deep value positioning for investors betting on operational turnaround. The -27.4% one-year return and negative margins attract contrarian investors seeking restructuring plays. Not suitable for income investors (no dividend) or momentum traders (negative price action). Appeals to special situations investors focused on margin expansion stories in healthcare devices, particularly those believing the 68.3% gross margin can translate to operating profitability with cost discipline.
high - Small-cap medical device companies with negative earnings and operational challenges typically exhibit elevated volatility. The $0.5B market cap creates liquidity constraints and susceptibility to large price swings on earnings reports or regulatory news. Beta likely exceeds 1.3-1.5x given sector, size, and profitability profile. Recent 6.3% quarterly decline indicates ongoing volatility as investors reassess turnaround timeline.
